Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
Pediatric Blood & Cancer2018Vol. 65(5), pp. e26969–e26969
Citations Over TimeTop 12% of 2018 papers
Asher Marks, Ranjit S. Bindra, Michael L. DiLuna, Anita Hüttner, Vikram Jairam, Kristopher T. Kahle, Mark W. Kieran
Abstract
Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials. Monotherapy with vemurafenib has been associated with significant side effects, including rashes, papillomas, and squamous cell carcinomas. Here we describe an adolescent female with anaplastic ganglioglioma and significant skin reaction to vemurafenib with subsequent tumor response and tolerance to the BRAF/MEK inhibitor combination of dabrafenib and trametinib without recurrence of previous reaction.
Related Papers
- → Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung(2018)8 cited
- → The Molecular Biology and Treatment of Malignant Melanoma with BRAFV600 Mutations(2014)1 cited
- → DI-030 Analysis of treatment with vemurafenib and dabrafenib in patients with metastasic melanoma in a tertiary hospital(2017)1 cited
- → Vemurafenib vs. Combination Dabrafenib/Trametinib(2014)
- → Focus on the dabrafenib, vemurafenib, and trametinib in clinical outcome of melanoma: a systematic review and meta-analysis(2020)